REM-422

· Remix Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for REM-422, covering 2025-04-23 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma [Phase 1, Phase 2]

See pricing